In vitro and ex vivo pharmacodynamics of selected non-steroidal anti-inflammatory drugs in equine whole blood

Veterinary Journal

Volumn 191, Issue 3, 2012, Pages 327-333

  Cuniberti, B ^a   Odore, R ^a   Barbero, R ^a   Cagnardi, P ^b   Badino, P ^a   Girardi, C ^a   Re, G ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Horse; Non steroidal anti inflammatory drugs; Pharmacodynamics; Whole blood assay

Indexed keywords

5 (4 CHLOROPHENYL) 1 (4 METHOXYPHENYL) 3 TRIFLUOROMETHYL 1H PYRAZOLE; ARACHIDONATE 5 LIPOXYGENASE; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ELTENAC; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; TEPOXALIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; EX VIVO STUDY; HORSE; IN VITRO STUDY; NONHUMAN; PHARMACODYNAMICS;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; FEMALE; HORSES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES;

EQUIDAE;

EID: 84857232555     PISSN: 10900233     EISSN: 15322971     Source Type: Journal    
DOI: 10.1016/j.tvjl.2011.03.016     Document Type: Article

References (39)

1. Argentieri D.C., Ritchie D.M., Ferro M.P., Kirchner T., Wachter M.P., Anderson D.W., Rosenthale M.E., Capetola R.J. Tepoxalin: A dual cyclooxygenase/5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. Journal of Pharmacology and Experimental Therapeutics 1994, 271:1399-1408.
2. 2α production in endometrial epithelial cells in vitro: Role of cyclooxygenase-2. Endocrinology 1997, 138:4798-4805.
3. Beretta C., Garavaglia G., Cavalli M. COX-1 and COX-2 inhibition in horse blood by phenylbutazone, flunixin, carprofen and meloxicam: An in vitro analysis. Pharmacological Research 2005, 52:302-306.
4. Berg J., Fellier H., Christoph T., Kremminger P., Hartmann M., Blaschke H., Rovensky F., Towart R., Stimmeder D. Pharmacology of a selective cyclooxygenase-2 inhibitor, HN-56249: A novel compound exhibiting a marked preference for the human enzyme in intact cells. Naunyn-Schmiedeberg's Archives of Pharmacology 2000, 361:363-372.
5. Bolego C., Buccellati C., Prada A., Gaion R.M., Folco G., Sala A. Critical role of COX-1 in prostacyclin production by human endothelial cells under modification of hydroperoxide tone. The FASEB Journal 2009, 23:605-612.
6. Brideau C., Van Staden C., Chan C.C. In vitro effects of cyclooxygenase inhibitors in whole blood of horses, dogs, and cats. American Journal of Veterinary Research 2001, 62:1755-1760.
7. Cagnardi P., Villa R., Zonca A., Carli S. Pharmacokinetics of eltenac in the horse after intravenous administration. Journal of Veterinary Pharmacology and Therapeutics 2006, 29:255.
8. Cagnardi P., Gallo M., Zonca A., Carli S., Villa R. Pharmacokinetics and effects of alkalisation during oral and intravenous administration of naproxen in horses. Journal of Equine Veterinary Science 2011, 10.1016/j.jevs.2011.03.019.
9. Capone M.L., Tacconelli S., Sciulli M.G., Anzellotti P., Di Francesco L., Merciaro G., Di Gregorio P., Patrignani P. Human pharmacology of naproxen sodium. Journal of Pharmacology and Experimental Therapeutics 2007, 322:453-460.
10. Caruso M., Zizzadoro C., Crescenzo G., Carofiglio V., Ormas P., Belloli C. Inhibitory effects of tepoxalin on COX1/COX2 and 5-LOX in equine whole blood. Journal of Veterinary Pharmacology and Therapeutics 2009, 32:108-109.
11. Charlier C., Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. European Journal of Medicinal Chemistry 2003, 38:645-659.
12. Cunningham F.M., Andrews M., Landoni M.F., Lees P. Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse. Journal of Veterinary Pharmacology and Therapeutics 1997, 20:296-307.
13. Dyke T.M., Sams R.A., Thompson K.G., Ashcraft S.M. Pharmacokinetics of multiple-dose administration of eltenac in horses. American Journal of Veterinary Research 1998, 59:1447-1450.
14. Funk C.D., Furci L., FitzGerald G.A. Polymerase chain reaction cloning and expression of eicosanoid metabolizing enzymes from blood cells. Advances in Prostaglandin, Thromboxane and Leukotriene Research 1991, 21A:33-36.
15. Giantin M., Cuniberti B., Re G., Dacasto M. Cloning, partial sequencing and expression of cyclooxygenase isoforms in the common digital artery of the horse: An in vitro study. Journal of Veterinary Pharmacology and Therapeutics 2006, 29:190-191.
16. Giorgi M., Cuniberti B., Ye G., Barbero R., Sgorbini M., Vercelli C., Corazza M., Re G. Oral administration of tepoxalin in the horse. A PK/PD study. The Veterinary Journal 2010, 190:143-149.
17. Giraudel J.M., Toutain P.L., Lees P. Development of in vitro assays for the evaluation of cyclooxygenase inhibitors and predicting selectivity of nonsteroidal anti-inflammatory drugs in cats. American Journal of Veterinary Research 2005, 66:700-709.
18. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: A new group of biologically active compounds derived from prostaglandin endoperoxides. Proceedings of the National Academy of Sciences 1975, 72:2994-2998.
19. Hamm D., Turchi P., Johnson J.C., Lockwood P.W., Thompson K.C., Katz T. Determination of an effective dose of eltenac and its comparison with that of flunixin meglumine in horses after experimentally induced carpitis. American Journal of Veterinary Research 1997, 58:298-302.
20. Huntjens D.R., Spalding D.J., Danhof M., Della Pasqua O.E. Correlation between in vitro and in vivo concentration-effect relationships of naproxen in rats and healthy volunteers. British Journal of Pharmacology 2006, 148:396-404.
21. Jones D.A., Carlton D.P., McIntyre T.M., Zimmerman G.A., Prescott S.M. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. Journal of Biological Chemistry 1993, 268:9049-9054.
22. Klein T., Dullweber F., Brehm C., Prinz W., Baudler M., Figala V., Herrmann M. Characterization of eltenac and novel COX-2 selective thiopheneacetic acid analogues in vitro and in vivo. Biochemical Pharmacology 2008, 76:717-725.
23. Lascelles B.D., King S., Roe S., Marcellin-Little D.J., Jones S. Expression and activity of COX-1 and 2 and 5-LOX in joint tissues from dogs with naturally occurring coxofemoral joint osteoarthritis. Journal of Orthopaedic Research 2009, 27:1204-1208.
24. Lees P., Higgins A.J. Clinical pharmacology and therapeutic uses of non-steroidal anti-inflammatory drugs in the horse. Equine Veterinary Journal 1985, 17:83-96.
25. Lees P., Landoni M.F. Pharmacodynamics and enantioselective pharmacokinetics of racemic carprofen in the horse. Journal of Veterinary Pharmacology and Therapeutics 2002, 25:433-448.
26. MacKay, R.J., Daniels, C.A., Bleyaert, H.F., Bailey, J.E., Gillis, K.D., Merritt, A.M., Katz, T.L., Johnson, J.C., Thompson, K.C., 2000. Effect of eltenac in horses with induced endotoxaemia. Equine Veterinary Journal, Suppl., 26-31.
27. Manrique-Moreno M., Suwalsky M., Villena F., Garidel P. Effects of the nonsteroidal anti-inflammatory drug naproxen on human erythrocytes and on cell membrane molecular models. Biophysical Chemistry 2010, 147:53-58.
28. Mitchell J.A., Akarasereenont P., Thiemermann C., Flower R.J., Vane J.R. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proceedings of the National Academy of Sciences 1993, 90:11693-11697.
29. Moses V.S., Bertone A.L. Nonsteroidal anti-inflammatory drugs. Veterinary Clinics of North America: Equine Practice 2002, 18:21-37.
30. Pairet M. Inhibition of cyclooxygenase-1 and cyclooxygenase-2 analysis of in vitro test systems and their clinical relevance. Journal of Clinical Rheumatology 1998, 4:17-25.
31. Panara M.R., Greco A., Santini G., Sciulli M.G., Rotondo M.T., Padovano R., di Giamberardino M., Cipollone F., Cuccurullo F., Patrono C., Patrignani P. Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2, 4-difluorothio-phenyl)-1-inda none (L-745, 337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthases. British Journal of Pharmacology 1995, 116:2429-2434.
32. Prügner W., Huber R., Lühmann R. Eltenac, a new anti-inflammatory and analgesic drug for horses: Clinical aspects. Journal of Veterinary Pharmacology and Therapeutics 1991, 14:193-199.
33. Rainsford K.D. Leukotrienes in the pathogenesis of NSAIDs induced gastric and intestinal mucosal damage. Agents and Actions 1993, 39:24-26.
34. Rocca B., Secchiero P., Ciabattoni G., Ranelletti F.O., Catani L., Guidotti L., Melloni E., Maggiano N., Zauli G., Patrono C. Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. Proceedings of the National Academy of Sciences USA 2002, 99:7634-7639.
35. Sayasith K., Sirois J., Dore M. Molecular characterization of feline COX-2 and expression in feline mammary carcinomas. Veterinary Pathology 2009, 46:423-429.
36. Suh H., Jun H.W., Lu G.W. Fluorimetric high performance liquid chromatography for quantitation of naproxen in serum. Journal of Liquid Chromatography 1995, 18:3105-3115.
37. Toutain P.L., Cester C.C., Haak T., Metge S. Pharmacokinetic profile and in vitro selective cyclooxygenase-2 inhibition by nimesulide in the dog. Journal of Veterinary Pharmacology and Therapeutics 2001, 24:35-42.
38. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: A full in vitro analysis. Proceedings of the National Academy of Sciences 1999, 96:7563-7568.
39. Zubrin (Tepoxalin) European Public Assessment Report, European Agency for Evaluation of Medicinal Products, EPARs for Authorised Medicinal Products for Veterinary Use, Rev. 11, 02/10/08.